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Abstract  
Cerebral cavernous malformations (CCM) are a group of homogenous lesions in 
the brain, spinal cord and retina that consist of focal sinusoidal dilatations of vasculature 
which can lead to devastating life-altering and/or life-ending events such as seizure and 
hemorrhagic stroke.   CCM exhibit compromised blood brain barrier due to perturbed 
endothelial cell to endothelial cell tight junctions, resulting in chronic hemorrhage.  
Linkage analysis has led to the identification of three loci which segregate to familial 
CCM (CCM1, CCM2 and CCM3).  Previous studies have identified PDCD10 as the gene 
responsible for CCM3.  Recent in vitro data have implicated PDCD10 in apoptosis and 
cell proliferation. 
Preliminary in vitro experiments demonstrate an increase in apoptosis after 
overexpression of PDCD10.  Introduction of mutations found in human CCM into the 
above expression vector failed to increase apoptosis.  Human umbilical vein endothelial 
cells (HUVECs) exposed to conditions of serum deprivation increased expression of 
CCM3 which preceded an increase in cleaved caspase-3.  Conversely, inhibition of 
PDCD10 expression through siRNA led to a decrease in cell death.  These experiments 
have been helpful in evaluating CCM3 function in vitro.  To assess the role of CCM3 in 
vivo, we have tissue-specifically knocked-out CCM3 utilizing Cre-recombinase mediated 
recombination of loxP-flanked CCM3 in mice.  Tie2 and GFAP promoters were used to 
drive Cre expression in endothelial cells and astrocytes respectively.  Our results indicate 
that CCM3 is important in the endothelium for early vascular development.   These 
mutant embryos exhibited morphology similar to that of CCM1 knockout mice.  Mice 
deficient in CCM3 in astrocytes exhibited dysmorphic features, such as an enlarged brain 
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and smaller body habitus when compared with control mice.  Histologically, cortical 
layering was perturbed in the mutant mice.  BrdU assays suggest that there is a decrease 
in dividing cells present in the superficial layers of the cortex.  Analysis of one adult 
mutant survivor led to the discovery of a CCM present near the cerebellar-pontine angle.  
Isolation of astrocytes from GFAP mutant mice revealed similar characteristics to our 
previous siRNA experiments using HUVECs.  Mutant astrocytes were resistant to 
cycloheximide induced apoptosis as measured by flow cytometry.  Our results support 
the current hypothesis that PDCD10 is a promoter of apoptosis.  These results also 
suggest that astrocytes play a critical role in the formation of CCM. 
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Introduction 
Vascular malformations of the cerebrum can lead to devastating life-altering 
and/or life-ending events such as seizure and hemorrhagic stroke.   These malformations 
can be categorized into five groups: 
arteriovenous malformations, arteriovenous 
fistulas, venous malformations, capillary 
telangectasias, and cerebral cavernous 
malformations.  Cerebral cavernous 
malformations (CCM) are a group of 
homogenous lesions in the brain, spinal cord 
and retina which consist of focal sinusoidal 
dilatations of vasculature.  CCM are 
characterized by a single layer of endothelium, 
lacking surrounding smooth muscle, elastin 
and central nervous system (CNS) 
parenchymal components.  Cavernous 
malformations manifest most commonly in 
the brain and spinal cord, but retinal and 
skin malformations are known findings [1], 
[2]. CCM exhibit compromised blood brain 
barrier due to perturbed endothelial cell to 
endothelial cell tight junctions, thus enabling 
Figure 1 MRI imaging of CCM. Courtesy of 
Murat Gunel MD  A. Sagittal & B.  Coronal 
MR images of a large CCM (arrowhead) that 
caused a gross hemorrhage (white arrows) in 
a child. C. & D. Axial images of the brain 
with the genetic form of CCM reveals 
multiple small hypointense lesions due to 
hemosiderin (arrows) . E. & F. Axial images 
show a typical venous malformation with 
multiple enlarged vessels (arrows) seen after 
IV administration of contrast material. This 
patient previously underwent successful 
surgery for removal of and associated CCM.  
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red blood cell deposition in adjacent parenchyma.  Radiographically, this chronic leakage 
can be identified by MRI as a hyper-intense ring of hemosiderin deposition surrounding 
the CCM (Figure 1).  Autopsy analyses suggest CCM prevalence to be around 0.5%.  
CCM make up around 10% of cerebral vascular malformations [3], [4].  Patients 
presenting with the clinical manifestations of CCM typically present between the third 
and fifth decades of life with seizure, focal neurological deficit or headache [5].  Seizures 
represent a common complaint of patients found to have CCM.  Studies of patients with 
CCM reveal seizure as the presenting symptom in fifty to sixty percent of the study 
groups [5], [6].  Symptomatic hemorrhage rates of CCM seem to be around 3% per 
patient year with female rates of hemorrhage being higher [7], [6].  CCM are known to 
occur sporadically, as well as familial.  Clinically, these two mechanisms are indistinct, 
but up to 85 percent of familial cases present with multiple lesions, as opposed to only 25 
percent of sporadic cases [8], [6].  CCM location correlates to the proportion of neural 
tissue through the neuroaxis with approximately eighty percent found supratentorally and 
roughly twenty percent of lesions found infratentorally [5], [6].  
 Significant advances have recently been made in understanding the genetic 
causes of CCM’s.  Specifically, linkage analysis has led to the identification of three loci 
which segregate to familial CCM.  These loci have been referred to as CCM1, CCM2 and 
CCM3 [9], [19], [31], [32].  The genes which correspond to these loci have been 
identified as Krev1/Rap1A Interaction Trapped 1 (KRIT1), MGC4607 (malcavernin) and 
Programmed Cell Death 10 gene (PDCD10).  Although genetic advances have been 
made, the molecular mechanisms leading to CCM formation, as well as, the temporal and 
spatial expression pattern and function of KRIT1, MGC4607 and PDCD10 continue to be 
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unknown.  Recent data have implicated these genes in interactions with the extracellular 
environment and apoptosis. 
CCM1 
 Linkage analysis and mutational screening identified a common mutation in Krev 
Interaction Trapped 1 (KRIT1) as the genetic source of cavernous malformations in 
thirty-one of forty-three Hispanic American kindreds originally from northern Mexico 
[9]. Further analysis of this locus, CCM1, revealed a loss of function mutation of the 
KRIT1 gene product [10], [9]. Studies using allele specific reverse transcriptase 
polymerase chain reaction have revealed germ line, as well as, somatic mutations present 
in malformations, but absent in peripheral blood; suggesting a two-hit hypothesis of 
CCM formation due to CCM1 [11]. 
 KRIT1 is a small GTP-binding protein originally identified because close 
homology with the Ras gene and its ability to revert the Ras transformation phenotype 
[12].  The ability to suppress the Ras oncogene has led to the hypothesis that KRIT1 is a 
tumor suppressor gene.  Analysis of the KRIT1 protein reveals multiple functional 
domains.  Earlier yeast two hybrid screens have identified Krit1 as a Rap1 binding 
partner [12].  Rap1 regulates integrin activation, formation of cell-cell junctions, cell 
adhesion [13], [14], [15], [16]. The interaction of Krit1 with Rap1 was confirmed in 2007 
by Beraud-Dufour et al. [17].  Using GST pull-down assays, they showed Krit1 
preferentially binding GTP-Rap1 through the Krit1 FERM (band four-point-
one/ezrin/radixin/moesin) domain.  FERM domains are known to allow proteins to 
interact with plasma membranes by binding plasma proteins and phosphoinositides [18] . 
In fact, Beraud-Dufour et al reported the ability of Krit1 to bind phosphatidyinositol 4,5-
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diphosphate.  This study also revealed the interaction of integrin cytoplasmic domain 
associated protein (ICAP) with Krit1 through an evolutionarily conserved NPxY 
(phosphor-tyrosine binding domain or PTB) domain present near the N-terminus.  
Additionally, they provided evidence that the amino and carboxy termini of Krit1 interact 
in a folded conformation which can be disrupted and straightened by binding to ICAP 
and that ICAP, Rap1 and Krit1 form a ternary complex in vitro.  This leads to the 
possibility that under certain conditions, Krit1 is transported along microtubules to the 
plasma membrane where it binds to GTP-bound Rap1, is opened by ICAP and modulates 
beta-integrin signaling. 
CCM2 
 Although CCM1 accounted for the majority of familial cases of CCM amongst 
the Hispanic population, familial CCM amongst non-Hispanics was not explained by this 
locus.  In 1998, Craig et al demonstrated linkage of CCM to two new loci in an outbred 
Caucasian population by genome-wide association studies.  These loci were located on 
the short arm of chromosome 7 (7p15-p13) and the long arm of chromosome 3 (3q25.2-
q27) [19]. In 2003 the gene which is responsible for CCM2 was revealed.  Liquori et al. 
[20] sequenced candidate genes found within the boundaries established by Craig et al 
1998.  This study found eight different mutations in the gene MGC4607 (malcavernin), 
each mutation, if translated, leading to a truncated gene product and possibly loss of 
function.  Interestingly, like ICAP, malcavernin possesses a phosphor-tyrosine binding 
domain (PTB) [20]. 
 Concurrent functional studies performed on a newly discovered scaffolding 
protein revealed an important role in the p38 signalling cascade.  It is well established 
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that the p38 MAP kinase pathway is an important mediator in stress induced cell survival 
[21], [22].  Uhlik et al (2003) [23] exposed HEK293 cells to a hyperosmotic sorbitol 
environment in order to activate the p38 MAP kinase pathway.  RNAi experiments 
against MEKK3 inhibited sorbitol induced activation of the p38 MAP kinase pathway.  
Using MEKK3 as bait in a yeast two-hybrid assay, a small PTB domain containing 
protein, similar to known adaptor and scaffold proteins, was identified [23]. RNAi 
knockdown of this gene resulted in near-complete inhibition of sorbitol mediated p38 
MAP kinase activation.  Immunostaining assays demonstrated the recruitment of this 
scaffold protein and MEKK3 to dynamic actin under hyperosmotic conditions.  The 
ability of this scaffold protein under hyperosmotic conditions to bind actin, recruit 
MEKK3 to Rac-GTPase containing sites for modulation of the p38 MAP kinase pathway, 
led the group to name this protein osmosensing scaffold for MEKK3 (OSM) [23]. 
 Furthermore, CCM2 (OSM) has been directly implicated in CCM1/ICAP/Beta 
Integrin signaling.  CCM2 can be co-immunoprecipitated with endogenous CCM1 in 
mouse embryonic fibroblast cells [24]. Introduction of a mutation into the CCM2 PTB 
domain completely prevented co-immunoprecipitation of CCM2 with CCM1.  
Specifically, the addition of a mutation, known to be present in a CCM kindred (L198R), 
which lies in the C-terminal area of the PTB domain present in CCM2 abolishes CCM2 
co-immunoprecipitation with CCM1.  Additionally, mutations introduced into a different 
NPxY domain on CCM1 known to be important for ICAP binding [25] failed to interfere 
with CCM1/CCM2 co-immunoprecipitation.  This finding leads to the hypothesis that 
CCM1 binds both ICAP and CCM2 through different NPxY/PTB binding interactions 
[18] , [24]. The binding of CCM1 partners to different NPxY domains implies that all 
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three have the potential to form a complex.  As predicted, 293T cells transfected with 
MEKK3, CCM1, CCM2 constructs; immunoprecipitated with CCM2 and then 
immunoblotted with CCM1 revealed the presence of both CCM1 and MEKK3 [24]. This 
provides evidence for a protein complex composed of at least CCM1, CCM2 and 
MEKK3.  
 mRNA expression and Subcellular localization studies have led to the hypothesis 
that co-expression of CCM complex constituents can lead to differential sequestration.  
Overexpression of a CCM1 construct in 293T cells reveals CCM1 existing in both 
cytoplasmic and nuclear compartments.  Overexpression of a CCM2 construct in the 
same cell line reveals the presence of CCM2 solely in the cytoplasm.  Co-expression of 
both constructs leads to CCM1 exclusion from the nucleus.  These findings support the 
conclusion that CCM2 binds to and sequesters CCM1 in the cytoplasm [24], [26]. 
ICAP and Beta 1-Integrins 
ICAP, like Krit1, contains a nuclear localization sequence.  Translocation of 
ICAP into the nucleus was demonstrated in osteoblasts seeded on beta-integrin substrate 
(fibronectin) coated plate.  ICAP mediated activation of the c-myc promoter and 
subsequent cell proliferation is dependent on this translocation [27]. Additionally, 
Overexpression of ICAP causes increased cell motility and adhesion to beta-integrin 
substrates [28]. 
Beta-1-integrins are a set of transmembrane receptors which bind the extracellular 
matrix (ECM) and, on the cytoplasmic side, constituents of the cytoskeleton.  Beta-1-
integrins are heterodimeric complexes, composed of one beta-1 subunit and one of a 
number of alpha subunits.  Mice lacking expression of the beta-1 subunit in radial glia 
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exhibit defects in connections of glial foot processes to the basement membrane of the 
meninges [29].  Studies using a neural progenitor promoter, Nestin, to drive Cre 
recombinase mediated deletion of beta 1-integrin, Belvindra, et al. [30] provided 
evidence that neural migration from the ventricular zone to the superficial layers of the 
cortex was not dependent on beta 1-integrin expression in neurons.  Additionally, 
neuronal projections and pyramidal neuron morphology was not perturbed in the Nestin 
driven knock-out.  In contrast, a mouse completely deficient of beta 1-integrin in the 
central nervous system exhibits greatly perturbed development of cortical layers and 
pyramidal neuron morphology; leading to the conclusion that beta integrin expression in 
radial glia is important for cortical layer and dendritic projection formation and guidance 
[30]. 
With this data from CCM1, CCM2, and ICAP studies, one could imagine a 
mechanism which consists of beta-integrin activation (possibly along with a co-stimulant) 
leading to CCM1 binding to ICAP and revealing the Talin binding site, allowing Talin to 
bind and leading to propagation of the beta-integrin signaling cascade modulating cell 
adhesion and migration.  Krit1 binding to ICAP, while also bound to malcavernin, brings 
malcavernin into close proximity with the plasma membrane where it can bind MEKK3 
and modulate the p38 signalling pathway.  It would be interesting to know whether (or 
when) malcavernin dissociates with the Krit1/ICAP complex, allowing Krit1/ICAP to 
translocate to the nucleus and effect cell proliferation, migration and/or adhesion.  
Elucidation of this mechanism would fail to address the role of CCM3 in the formation of 
cerebral cavernous malformations. 
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CCM3 
 CCM1 and CCM2 mutations account for around sixty percent of familial forms of 
the disease [31], [32]. A third locus linked to the familial formation of CCM was 
discovered in 2005 [31], [32]. This new locus, CCM3, was found to harbor mutations in 
programmed cell death gene 10 (PDCD10).  This gene is member of a family of genes 
known to be important in regulation of apoptosis.  PDCD10 was originally described as 
being upregulated in a premyeloid cell line after 8 hours of granulocyte-monocyte colony 
stimulating factor (GM-CSF) deprivation and activation of apoptosis [33]. Subsequent 
studies have found PDCD10 to be upregulated in skeletal muscle after denervation [34] 
and in cultured fibroblasts after exposure to cycloheximide [35]. Unfortunately, increased 
expression of the gene in response to apoptotic stimuli does not explain function as cell 
survival components could be upregulated, as well as, cell death constituents under 
apoptotic conditions.  siRNA experiments against PDCD10 in human prostate cancer cell 
line (PC-3) cultures led to decreased proliferation, as measured by a tetrazolium salt 
assay, over 120 hours.  Furthermore, MST4, a Sterile-20 protein kinase, dependent 
activation of PC-3 proliferation was inhibited by PDCD10 siRNA [36]. MST4 is a known 
modulator of the extracellular-regulated kinase (ERK) pathway [37]. These results 
directly implicate PDCD10 in modulation of ERK signaling.  It is unclear where 
PDCD10 lies in the ERK signaling pathway.  In the PC-3 cultures experiments, it seems 
that PDCD10 is downstream of MST4.  Another possibility is that PDCD10 is part of a 
synergistic pathway that, when lost, prohibits the proliferative signals from ERK/MST4 
activation.  Of interest, integrin signaling has been implicated in the modulation of 
mitogen activated protein (MAP) kinase/ERK pathway [38]. This data provides insight 
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into the possible connection between beta integrin activation, PDCD10 and ERK 
signaling pathway.  
 CCM3 may bind to CCM2 and its function may be regulated by phosphorylation. 
Yeast two-hybrid, in vitro co-immunoprecipitation and GST pull downs have identified 
serine/threonine kinase 25 (STK25) and Fas-associated phosphotase (FAP-1) as binding 
partners for CCM3.  STK25, in vitro, possessed the ability to phosphorylate CCM3.  
While FAP-1’s catalytic domain possessed the ability to de-phosphorylate CCM3 [39]. 
Overexpression of CCM3 in HEK293 cells along with CCM2 and CCM1 resulted in 
CCM3 co-immunoprecipitating with CCM2, but not with CCM1 [39]. Additionally, 
mutations known to be present in familial CCM have been shown to disrupt the ternary 
CCM complex in vitro [40].  These findings support the hypothesis that CCM3 does not 
bridge binding of CCM1 to CCM2, but binds directly to CCM2 and not CCM1.  The 
relationship between CCM1 and CCM3 is dependent on CCM2. 
 
Statement of Purpose 
 The purpose of our experiments is to further elucidate the function of CCM3.  We 
will achieve this by using a conditional mouse knock-out of CCM3.   Specifically, we 
have utilized the bacteriophage derived Cre-recombinase deletion of DNA sequence 
flanked by sequence specific loxP sites.  We have used cell line specific promoters to 
drive Cre-recombination of CCM3-loxP flanked alleles.  A mouse harboring a 
CCM3floxed allele was generated in the laboratory of Wang Ming PhD (Department of 
Pathology, Yale School of Medicine).  For the endothelial cell knock-out, the Tie2 
promoter was used to drive Cre-recombinase.  This mouse was developed in the 
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Yanagisawa lab (UT Southwestern).  This promoter is known to drive recombination in 
endothelial cells present in the embryo, as well as, the yolk sac beginning around e8.5 
[41]. Cre-recombination in neural progenitors was driven by the Nestin promoter.  This 
mouse was obtained through Jackson Laboratories and is known to express Cre at 
embryonic day 11.  Astrocytes, oligodendrocytes, ependymal cells and a subset of 
neurons were targeted for Cre-mediated deletion of CCM3 under the control of the glial 
fibrillary acidic protein (GFAP promoter).  This mouse was obtained from Jackson 
Laboratories and is known to mediate recombination in the above cell lines by e13.5. 
We believe knocking-out CCM3 in cells present in the CNS will lead to CCM 
formation and possibly an increased number of cells present in the CNS, either by 
increased proliferation or decreased apoptosis.  We have also used human umbilical 
endothelial cells and primary murine astrocytes exposed pro-apoptotic conditions to study 
the function of CCM3 in vitro.  We believe CCM3 to be important in the apoptotic 
pathway. Furthermore, we believe the absence of CCM3 will lead to decreased apoptosis. 
 
Preliminary Data (data performed by others in the lab of Murat Gunel MD) 
PDCD10 overexpression promotes cell death 
 
 Transfection of HELA cells with the construct pEGFP(C3)-hCCM3 led to an 
increase in terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling 
(TUNEL) as compared to HELA cells transfected with an empty GFP construct.  HELA 
cells transfected with a CCM construct displayed morphologic changes consistent with 
apoptosis, fragmented nuclei, and exhibited increased expression of caspase-3 (Figures 2  
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Figure 2 CCM3 induces apoptosis in HeLa cells.  Courtesy of Leiling Chen MD and Murat 
Gunel MD. HeLa cells were transfected with GFP-CCM3 or GFP constructs and then serum-
starved starting seven hrs after transfection. 50 hrs after transfection, cells were fixed, and nuclei 
stained with DAPI (blue).  Arrows point to the GFP-CCM3-positive cells (green) with condensed 
or fragmented apoptotic nuclei.  Scale bar = 20 μm (a).  GFP-positive cells were quantified for 
apoptosis by scoring apoptotic nuclear morphology as in (a).  The percentage of GFP-positive 
cells with apoptotic nuclei was represented as mean + SEM from three (n = 5) and four (n = 14) 
independent experiments for the 25 and 50 hr timepoints, respectively (left panel).   *P < 0.002, 
significant difference from GFP-transfected cells; #P < 0.001, significant difference from GFP-
transfected cells (by Student’s t-test) (b).  Protein expression of GFP and GFP-CCM3 25 hrs after 
transfection was confirmed by immunoblotting with anti-GFP.  Anti-actin was used as a control 
for loading (right panel) (c).   
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Figure 3 CCM3 activates caspase-3 in HeLa cells.  Courtesy of Leiling Chen MD and Murat Gunel MD.  (a) 
HeLa cells were transfected with RFP-CCM3 or RFP constructs and then serum-starved starting seven hours 
after transfection.  40 hrs after transfection, cells were fixed and immunostained with FITC-anti-active Caspase-
3 (green), and nuclei were labeled with DAPI (blue).  Arrows point to RFP-CCM3-positive cells (red) that are 
active Caspase-3 immunoreactive.  Arrowheads represent transfected cells that are not active Caspase-3 
immunoreactive.  Scale bar = 20 μm. (b) RFP-positive cells were assessed for Caspase-3 activation by scoring 
active Caspase-3-immunoreactivity as indicated in (a).  Histogram represents mean + SEM from three (n = 7-
10) independent experiments for the 25 hr and 40 hr timepoints, respectively.  *P < 0.001, significant difference 
from RFP-transfected cells; #P < 0.001, significant difference from RFP-transfected cells (by Student’s t-test).    
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and 3).  This data is consistent with the hypothesis that overexpression of CCM3 leads to 
apoptosis. 
 Introduction of 
mutations reported to be 
present in kindreds of CCM 
(c.283C>T and c.194delA), 
which result in a truncated gene 
product, into the above 
expression vector failed to 
increase the amount of cleaved 








 Human umbilical vein 
endothelial cells cultured in the 
absence of fetal bovine serum 
(FBS) resulted in increased 
expression of cleaved caspase-
3 after three hours (Figure 5a).  
Interestingly, CCM3 expression preceded the increased expression of cleaved caspases-3.  
Figure 4 Mutated CCM3 fails to induce apoptosis Courtesy of 
Leiling Chen MD and Murat Gunel MD.  (a) Transfection with 
wildtype CCM3 increases cleaved caspase 3 expression levels, 
while transfections with either mutated CCM3 construct has no 
effect on cleaved caspase 3 expression.  Legend: N= 
transfection reagent alone, V= GFP vector alone, CCM3= 
transfection with wildtype pEGFP-hCCM3 vector, M1 = 
transfection with pEGFP-hCCM3 vector containing the 
c.283C>T mutation, M2 = transfection with pEGFP-hCCM3 
vector containing the c.194delA mutation.  (b) Control western 
probed for anti-GFP (Sigma Aldrich,  MO ) demonstrates 
transfection efficiency. Legend: N= transfection reagent alone, 
V= GFP vector alone, CCM3= transfection with wildtype 
pEGFP-hCCM3 vector, M1 = transfection with pEGFP-
hCCM3 vector containing the c.283C>T mutation, M2 = 
transfection with pEGFP-hCCM3 vector containing the 
c.194delA mutation.  (c) Transfections with mutated CCM3 
shows reduced cell loss compared to wildtype CCM3. Cell 
viability was measured using the 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyl tetrazolium (MTT) assay and is graphed as a 
percentage of the control culture value (GFP plasmid 
transfection group) as quantified by determining the 
absorbance of cell cultures at 550 nm. Asterisk denotes P < 
0.05 vs. GFP plasmid transfection group. 
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Increased CCM3 expression was noticeable as soon as thirty minutes after withdrawal of 
FBS (Figure 5b).  The observed increase in CCM3 expression was reversible after 
reintroduction of FBS into the cell culture medium (Figure 5c).  To confirm the effect of 
serum deprivation on CCM3 transcription, cultures were exposed to the transcription 
inhibitor actinomycin D.  Actinomycin D inhibited the transcription, and therefore 
translation, of CCM3 (Figure 5d). 
Figure 5 Serum-starved endothelial cells result in apoptosis, increased CCM3, activated Caspase 3, 
and p38 levels. Courtesy of Leiling Chen MD and Murat Gunel MD.  (a) Serum-deprived HUVECs 
demonstrate an increase in cleaved caspase 3 levels by hour 3.  Graphed densitometric analysis of 
cleaved caspase 3 is normalized to GAPDH. (b) CCM3 expression increased upon serum-
deprivation starting at approximately 30 minutes, prior to the increase in cleaved caspase-3 levels as 
demonstrated by (a).  (c) Addition of serum to cell culture rescues CCM3 expression.  The x-axis 
denotes the addition (+) or absence (-) of different concentrations of FBS (normal=20%, 
deprivation=0.2%) over different time points.  The graphed densitometric analysis of cleaved 
caspase 3 is normalized to GAPDH as demonstrated by the western blot above.  (d) Cell cultures 
were incubated with various concentrations of Actinomycin D (x-axis, top), a transcription inhibitor 
at time=0 and =1 hour (x-axis, bottom).  Actinomycin D treatment inhibits CCM3 expression 
confirming that serum starvation causes an increase in CCM3 transcription.  (e) Serum deprivation 
results in an increase in activated (p-) p38 prior to activated caspase 3 activation as demonstrated by 
(a).  Levels of p-p38 increase dramatically upon serum starvation at 6 minutes, followed by a second 
peak beginning at 3 hours. 
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 Given the known effect of CCM1/CCM2 signaling on the MAP kinase/p38 
pathway, our group investigated how serum deprivation effected p38 activation.  Serum 
deprivation increased the abundance of phosphorylated p38.  The increase of 
phosphorylated p38 preceded the increase in CCM3 expression and also cleaved caspase-
3 (Figure 5e). 
PDCD10 siRNA 
decreases cell death 
 
 Under the FBS 
deprivation conditions 
described above, 
HUVECs were exposed 
to PDCD10 siRNA.  
Inhibition of PDCD10 
led to decreased TUNEL 
positivity which reached 
statistical significance at 
3 hours (Figure 6a).  
PDCD10 siRNA also led to 
muting of the increased level 
of cleaved caspase-3 seen 
under serum deprivation (Figure 6b).  Additionally, PDCD10 siRNA conditions led to an 
attenuated increase in p38 expression (Figure 6c).  This data further implicates CCM3 in 
the CCM1/CCM2 signaling pathway. 
Figure 6 siRNA inhibition of CCM3/PDCD10 expression results in 
decreased cell death, p38, and activated Caspase-3 expression. 
Courtesy of Leiling Chen MD and Murat Gunel MD. (a) HUVECs 
treated with PDCD10 siRNA demonstrate decreased p38 expression 
levels compared to controls.  (b) Serum-deprived HUVECs treated 
with PDCD10 siRNA show decreased apoptosis.  (c) Serum-starved 
HUVECs show decreased activated caspase 3 levels after treatment 
with PDCD10 siRNA. 
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 The above in vitro experiments provide strong evidence of CCM3’s role in 
apoptosis.  Overexpression of CCM3 led to increased morphological changes consistent 
with apoptosis, as well as, increased expression of the pro-apoptotic gene caspases-3.  
Serum deprivation experiments led to increased expression of CCM3, p38 and cleaved 
caspase-3.  PDCD10 siRNA experiments led to an attenuation of the pro-apoptotic 
response.  These results suggest that PDCD10 acts as a regulator of apoptosis.  
Specifically, PDCD10 expression promotes apoptosis.  PDCD10 may act as in a tumor-
suppressor like manner.  Loss of PDCD10 function may lead to decreased apoptosis in 
vivo. 
GFAP-Cre;CCM3lox/lox mice exhibit multiple developmental abnormalities 
 
 Mutant (GFAP-Cre;CCM3lox/lox) mice are born according to the expected 
Mendelian ratio, although many fail to survive past weaning.  Mutant mice weigh less 
and possess smaller bodies than littermate control animals, but have larger brains (Table 
1).  Mutant mice display severe ataxia, often moving in a circle. 
 Expression of CCM3 mRNA, as measured by in situ hybridization, is reduced in 
the mutant CNS.  Expression was not completely ablated and is expected to be 
unperturbed in the endothelium and most neurons (Figure 7). 
Table 1 Analysis of GFAP-Cre;Ccm3lox/lox animals reveals small body size but enlarged brain. Brain 
weight when corrected for body weight is 1.5-2.7 times that of control littermates.  Courtesy of 
Angeliki Louvi PhD and Murat Gunel MD 
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 Expression of GFAP is 
increased throughout the 
mutant CNS (Figure 8).  The 
increase in GFAP expression 
could be a product of increased 
proliferation of GFAP 
expressing cells or a decrease 
in apoptosis present in the early 
development of the CNS.  The 
large axon tracts of the corpus 
callosum are substantially thinner 
in the mutant brain.  This result is evident upon sectioning, as well as, MRI and 
represents either a perturbation of myelination or a perturbation of axonal migration 
(Figures 8 and 9).  Enlarged CNS vasculature was a finding which was observable by 
MRI and sectioning (Figures 9 and 
10).  Cerebrovascular capillaries, 
identified through in situ 
hybridization, were disorganized 
compared to control CNS, often 
lacking a vertical orientation (Figure 
11).  Analysis of the cerebellum 
through immunohistochemistry with 
antibodies against neurofilament 









Figure 7 Ccm3 mRNA (lower panel), is significantly 
downregulated in the brains of GFAP-Cre; Ccm3lox/lox 
animals (lower right). As a control, we evaluated 
Ccm2 mRNA in both experimental and control 
animals as well and found it be unaltered (upper 
panels).  Courtesy of Angeliki Louvi PhD and Murat 
Gunel MD 
Figure 8 GFAP staining of GFAPCre;PDCD10-/- 
mouse (right panel) at P21 as compared to controls (left 
panel) reveal increased glial cell numbers and brain 
mass in the experimental animals.  Courtesy of Angeliki 
Louvi PhD and Murat Gunel MD
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revealed a lack of Purkinje cell 
monolayers, possibly 
accounting for the problems 
with gait observed in mutant 
mice (Figure 12). 
 Most GFAP-
Cre;CCM3lox/lox mice do not 
survive past weaning.  Analysis 
of five mutants which survived 
past weaning revealed a 
persistent weight discrepancy 
between mutant and control, 
with the mutants weighing on 
average 80% that of the control 
mice.  One adult mutant 
presented with two superficial 
vascular malformations one 
near the olfactory bulb and the 
other near the pons (Figure 13).  
These malformations are very 
similar to lesions present in 
patients with CCM.  MRI performed on two additional adult mutants revealed the 
presence of dilated vasculature, a finding common in human CCM (Figure 9). 
Figure 9 MRI imaging of a live 8 month GFAP-Cre;Ccm3lox/lox 
mice reveals enlarged vessels (red arrows) in A. and B. 
Interestingly, fractional anisotrophy detects thinner while 
matter in corpus callosum in experimental animal (red arrow) 
compared to a littermate D. Please note the larger brain size of 
the mutant in C. as compared to D.  Courtesy of Murat Gunel 
MD 
Figure 10 Histological examination of the brain of the 
GFAP-Cre;Ccm3lox/lox mutants reveal enlarged vessels (red 
arrows).  Courtesy of Angeliki Louvi PhD and Murat Gunel 
MD 
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Deletion of CCM3 effects proliferation and apoptosis in primary astrocyte culture 
 
 Astrocytes were isolated from GFAP-Cre;CCM3lox/lox and GFAP-Cre;CCM3lox/+ 
mice as described below.  Cells were plated at equal concentrations and allowed to grow 
in culture for 1, 2, and 3 days.  Proliferation was measured by 3-(4,5-Dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT, a tetrazolium salt) assay on each day.  
Reduction of the tetrazolium salt in the mitochondria can be measured using a 
Figure 11 The organization of the cerebrovascular capillaries appear less orderly in the experimental animals (right 
panel) at P6 compared to controls (left panel) based on Col4a1 in-situ hybridization.  Courtesy of Angeliki Louvi 
PhD and Murat Gunel MD 
Figure 12 Purkinje cells are disorganized and appeared supernumerous in the cerebellum of the P16 experimental 
animals (right panel) as compared to controls (left panel) and as shown by axonal staining with neurofilament  
fluorescence.  Courtesy of Angeliki Louvi PhD and Murat Gunel MD 
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spectrophotometer and correlates to the number of viable cells in culture.  GFAP-
Cre;CCM3lox/lox cultures displayed a growth advantage at day 1, which persisted through 
day 3 (Figure 14). 
 The increased MTT signal in the GFAP-Cre;CCM3lox/lox cultures could be 
explained by decreased apoptosis, increased proliferation or both.  To further elucidate 
life cycle changes, cultures were analyzed by immunohistochemistry using antibodies 
against Ki67, a known marker of proliferation.  GFAP-Cre;CCM3lox/lox cultures exhibited 
increased proliferation within 24 hours as compared to GFAP-Cre;CCM3lox/+ cultures 
(Figure 15).  This result was confirmed by BrdU assays (Figure 16). 
 Next, our group exposed primary astrocytes to cycloheximide, a known inducer of 
apoptosis.  GFAP-Cre;CCM3lox/lox cultures did not undergo apoptosis as GFAP-
Figure 13 CCM lesions in a 7 month old 
GFAPCre;PDCD10-/- mouse. Multiple CCM 
lesions, two within the olfactory bulb and a large 
lesion on the cerebellum (red circles) are seen 
(upper left panel). Higher magnification (lower 
left panel), reveals enlarged vessel (arrow) around 
the CCM lesion which is a common finding in 
human CCM disease (associated venous 
malformation). Right upper panel shows an 
enlarged view of the cerebellar lesion with 
characteristic CCM caverns.  Courtesy of Angeliki 
Louvi PhD and Murat Gunel MD 
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Cre;CCM3lox/+ cultures, as 
measured by TUNEL (Figure 17).  
Additionally, cycloheximide 
induced an increase of cleaved 
caspase-3 in the GFAP-
Cre;CCM3lox/+ culture.  This effect 
was attenuated in the GFAP-
Cre;CCM3lox/lox culture (Figure 
18). 
Deletion of CCM3 effects integrin 
dependent cell function 
 
 Beta-1 integrin’s role in 
cell adhesion and migration is well 
established [42], [43] [44], [45]. Cell migration was tested by allowing cultures to grow 
to confluence then scratching the culture dish with a pipette tip.  Migration through the 
cell free zone was stunted in the GFAP-Cre;CCM3lox/lox cultures and continued to trail the 
GFAP-Cre;CCM3lox/+ cultures through 48 hours (Figure 19). 
 Cell adhesion was tested using three different substrates (Figure 20).  Neither 
culture adhered well to vitronectin.  Both GFAP-Cre;CCM3lox/lox and GFAP-
Cre;CCM3lox/+ cultures exhibited a higher affinity to the beta-1 integrin substrates, 
fibronectin and laminin.  Although the GFAP-Cre;CCM3lox/lox cells tended not adhere as 
well to beta-1 integrin substrates, the difference is insignificant.  The question remains of 
how the GFAP-Cre;CCM3lox/lox cultures would compare to a wild-type control. 
Figure 14 CCM3 deletion induced increase in 
proliferation was evaluated with MTT assay. 
Astrocytes were seeded at 1 × 102/cm2 on poly-L-
ornithine coated 96 well plates.  The cells were 
allowed to attach overnight. At different time point 
(day 1, 3, 5 ), add 20 ul of MTT solution (5mg/ml) to 
each well containing cells. The absorbance was read at 
550nm.  Courtesy of Leiling Chen MD and Murat 
Gunel MD 
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Figure 15 Alternatively, CCM3 deletion induced 
increase in proliferation was evaluated with ki67 
immunohistochemistry staining: Astrocytes were 
seeded on poly-L-ornithine coated 4 well culture 
slides. At different time point, the cells were fixed in 
4%PFA, and the percentage of positive ki67 per high 
field (x40) was count. The photo-imagine show the 
representative imagine for the ki67 immunostaining at 
24 hours culture (x20). The positive ki67 is green and 
nuclear staining, the blue is DAPI counter staining. A. 
control astrocyte; B Mutant astrocyte; C. quantization 
of positive ki67 percentage.  Courtesy of Leiling Chen 
MD and Murat Gunel MD 
Figure 16 Furthermore, CCM3 deletion 
induced increase in proliferation was 
evaluated with BrdU incorporation assay: 
Astrocytes were seeded on poly-L-
ornithine coated 4 well culture slides, and 
incubated with 10um BrdU. At different 
time point, the cells were fixed in 4%PFA, 
and the percentage of positive BrdU per 
high field (x40) was count. The photo-
imagine show the representative imagine 
for the BrdU immunostaining at 24 hours 
culture (x20). The positive BrdU is green 
and nuclear staining, the blue is DAPI 
counter staining. A comes from control 
(GFAP Cre;lox/+); B comes from mutant 
(GFAP Cre; lox/lox).  Courtesy of Leiling 
Chen MD and Murat Gunel MD 
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Methods (performed by 
author) 
Mouse Colony.   
Experiments were carried out 
in accordance with protocols 
approved by the Institutional 
Animal Care and Use 
Committee at Yale 
University School of 
Medicine. Mouse colonies 
were maintained at Yale 
University, in compliance with National Institutes of Health guidelines and with the 
approval of Yale University Institutional Animal Care and Use Committee. To generate 
experimental animals, males with the genotype of Promoter-Cre;CCM3lox/+ were mated 
with females lacking the Cre transgene and possessing a CCM3lox/lox genotype.  For timed 
pregnancies, midday of the day of vaginal plug discovery was considered embryonic (e) 
day 0.5. Mice at embryonic and postnatal stages through adulthood were used. For 
embryonic stages, pregnant females were anesthetized and pups at appropriate stages 
were dissected from the uterus. Embryonic brains/neural tubes were dissected and fixed 
by immersion in 4% paraformaldehyde (PFA) in phosphate buffered saline (PBS) 
overnight. Mouse pups [postnatal (P) day 0 through P2] were anesthetized on ice, then 
the brains were removed and fixed in 4% PFA overnight. At all other stages, mice were 
anesthetized and intracardially perfused with 4% PFA.  
Figure 18 CCM3 deletion in astrocyte results in resistance of 
cycloheximide induced apoptosis: . Astrocytes were seeded at 
2 × 105 on poly-L-ornithine coated 10cm plates, and incubated 48 
hours, then 20ug/ml cycloheximide was added into medium.  At 
different time point, cells were lysed, and followed with western 
blotting.  Courtesy of Leiling Chen MD and Murat Gunel MD 
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DNA Preparation from Mouse Tissue.  Tissue 
was collected from the mouse for genotyping. 
For embryonic mouse stages the yolk sac was 
taken and for later stages (postnatal day 0 or 
older) a small portion of tail was taken. The 
tissue was combined with 90 μl of sterile water 
and incubated at 95°C for 10 minutes. The 
samples were briefly spun down and brought 
down to room temperature (2-3 minutes). 10 
μl of proteinase K (at 2 μg per μl 
concentration) was added and mixed well. The 
samples were then incubated at 55°C 
overnight and then 95°C for 10 minutes to 
inactivate the proteinase K. After 
centrifugation the resulting supernatant was 
used for PCR analysis.  
 
PCR. PCR was performed to genotype the transgenetic mouse lines used in this study. 
The standard reaction contained 10 μl 2x FailSafeTM Buffer Premix F (Epicentre,  
Madison, WI), 0.3 μl of 10 μmol of each primer, 0.5 μl of DNA, and 0.2 μl of Taq DNA 
polymerase isolated from an E. coli strain that carries the DNA polymerase gene from T. 
aquaticus. The amplification protocol was comprised of a denaturation step at 95°C for 4 
Figure 19 : Deletion of CCM3 results in 
Deletion decreased migration of astryocte. 
Astrocytes are plated in tissue culture 
dishes (10mg/ml poly-L-ornithine coated), 
and after 24 h of incubation, the confluent 
monolayer of cells was scratched in a 
standardized manner with a plastic tip to 
create a cell-free zone in each well, 2 mm 
in width. The medium was aspirated and 
replaced with DMEM/F12 plus 10% FBS. 
At desired time point, the cells were fixed 
in 4%PFA, and stained using 0.1%crystal 
violet. In vitro re-epithelialization was 
documented by photography.  Courtesy of 
Leiling Chen MD and Murat Gunel MD 
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min, followed by 35 
cycles of a 95°C 
denaturation step for 30 
sec, an annealing step at 
55°C for 30 sec, and a 45 
sec extension step at 
72°C.  The reaction was 
completed with a 10 min 
extension step at 72°C. 
The primers used to for 
genotyping were as 
follows: Cre primer 1, 
CCGGGCTGCCACGACCAA; Cre primer 2, GCGCGGCAACACCATTTTT, CCM3 
primer 1, CTCAGTGTAGTCATGAAAAGAGT; CCM3 primer 2, 
CCAGCATCCTTTGCCTCTCC. The Cre primer set generated a 500 base pair product. 
The CCM3 primers resulted in a 150 base pair product for the knock-out genotype 
compared to a 103 base pair product for the wild-type genotype. PCR products were 
analyzed using gel electrophoresis. 
 
Riboprobe synthesis for in situ hybridization. Templates for riboprobe synthesis were 
derived from cloned mouse cDNA sequences of the corresponding genes: T-box brain 
gene 1 (TBR1), Chick ovalbumin upstream transcription factor I (COUP-TFI), Calbindin 
(CALB), Pou Domain, class 3, transcription factor 1 (SCIP),  Ephrin A5, Notch, 
Figure 20 CCM3 deletion results in no change in adhesion of astrocye 
to extracellular matrix. Murine lamnin-1, bovine fibronectin, and 
bovine vitronectin will be obtained from Sigma. 10ug/ml of ECM 
solution is added on Petri dish 2 hous at 37ºC. Before addition of 
cells, all substractes were blocked with heat-inactivated bovine serum 
albumin to prevent non specific binding the substrates. After washed 
with PBS, the cells (2x103) added for 30 minutes. The adhesion assay 
is stopped by adding DMEM/F12 plus 10% FBS to the Petri dish and 
washed off loosely attached cells. The attached cells are then fixed 
with 4% paraformaldehyde in PBS for 20 minutes. Adhesion was 
quantified counting all attached cells under phase microscopy. 
Courtesy of Leiling Chen MD and Murat Gunel MD
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Retinoid-related orphan receptor alpha (RORα), β-tublin. The constructs were 
previously made and consisted of the cDNA inserted 3’ to 5’ in respect to a T7 promoter 
in a plasmid DNA backbone. This design allows for an anti-sense RNA transcript to be 
synthesized utilizing T7 RNA polymerase and digoxigenin-11-UTP. Before RNA 
synthesis, plasmids were first linearized with a restriction enzyme digest. After digestion, 
the reaction was treated with 0.005% sodium dodecyl sulfate (SDS) and proteinase K 
(final concentration of 0.7 mg/ml) for 15 minutes at 37°C. The DNA templates were then 
purified using a phenol/chloroform/isoamyl alcohol extraction. Briefly, a 
phenol/chloroform/isoamyl solution (25 parts phenol to 24 parts chloroform to 1 part 
isoamyl alcohol) was added at an equal volume to the DNA sample. After inverting 
several times, the samples were spun down at 14,000 rpm for 5 minutes and the aqueous 
phase (top layer) was transferred to a new tube. An equal volume of chloroform/isoamyl 
alcohol (24 parts chloroform to 1 part isoamyl alcohol) was then added, mixed well, 
centrifuged down at 14,000 rpm for 5 minutes, and the aqueous layer was removed again. 
This last step was repeated once more. An ethanol precipitation of the DNA was then 
performed by adding 2.1 times the volume of 100% ethanol and 0.1 times the volume of 
3 M sodium acetate. The DNA was incubated on ice for 15 minutes and spun down at 
14,000 rpm for 15 minutes at 4°C. The supernatant was discarded and the pellet was 
washed with 70% ethanol and centrifuged at 14,000 rpm for 5 minutes. The pellet was 
allowed to dry and resuspended in 20 μl of DEPC-treated H20. This linearized and 
purified DNA was then used as the template DNA for riboprobe transcription. The 
transcription reaction consisted of 1 μg of DNA, 2 μl of 10x transcription buffer, 2 μl of 
nucleotide mixture (containing digoxigenin-11-UTP), 1 μl RNase Inhibitor, 1 μl of 100 
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mM DTT, and 2 μl T7 RNA polymerase. The reaction was incubated at 37°C for 2 hours. 
2 μl of DNase was then added and incubated for 15 minutes at 37°C.  The RNA was 
precipitated by adding 100 μl of DEPC-treated H20, 10 μl of lithium chloride and 300 μl 
of 100% ethanol and incubated on ice for 15 minutes. The RNA was pelleted by spinning 
at 14,000 rpm for 15 minutes at 4°C and washed once with 70% ethanol. After drying the 
pellet, the riboprobe was resuspended in 100 μl of DEPC-treated H20 and checked for 
quality on an agarose gel.  
 
In situ hybridization. Mouse brains were post-fixed overnight in 30% sucrose/4% PFA 
and sectioned in the coronal plane on a Leica sledge cryomicrotome at 36 μm (Leica 
Microsystems, Germany). Sections were mounted on slides and allowed to dry overnight 
before further processing. For the in situ hybridization all incubation and wash steps were 
performed on a rocker when possible in RNase-free conditions.  The slides were first 
treated with 4% PFA for 15 minutes and wash 3 times for 5 minutes each in DEPC-PBS. 
For mouse stages P0 through P20 the slides were incubated in detergent solution 
(consisting of) for two 15 minute intervals. For older stages, 30 minute incubation 
periods were used and no detergent treatment was used for embryonic tissue sections. 
After detergent treatment, the slides were washed once in DEPC-PBS and then incubated 
with proteinase K solution (at a concentration of 1.02 μg/ml) for 30 minutes at 37°C.  
Slides were fixed again in 4% PFA for 15 minutes and then washed three times 5 minutes 
in DEPC-PBS. Then the slides were pre-incubated in hybridization solution (consisting 
of) at 70°C for an hour. 70 μl of the prepared riboprobe (see above) was added to 14 ml 
of hybridization and mixed. Slides were incubated in the riboprobe solution overnight at 
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70°C. The following day slides were washed in a stringent wash (containing 
formaldehyde) three times for 45 minutes each at 70°C. Then three washes with Tris-
buffered saline containing 0.1% Tween-20 (TBST) were performed. The slides were 
placed in blocking step in 10% lamb serum in TBST for 60 minutes prior to incubation 
with an alkaline phosphotase conjugated anti-DIG antibody (at a 1:5000 concentration in 
1% lamb serum TBST) for 2 hours at room temperature. Three washes in TBST for 15 
minutes were done before developing with 5-Bromo-4-Chloro-3'-Indolyphosphate p-
Toluidine Salt (BCIP) and Nitro-Blue Tetrazolium Chloride (NBT). Development time 
differed depending on the riboprobe ranging from overnight to 2 days. Afterwards the 
slides were dehydrated in a series of ethanol steps, cleared with Histoclear (a xylene 
substitute) and cover-slipped. Sections were analyzed using a Zeiss Stemi dissecting 
microscope or a Zeiss AxioImager (Zeiss, Oberkochen, Germany) fitted with an 
AxioCam Mrc5 digital camera. Images were captured using AxioVision AC software 
(Zeiss) and assembled using Adobe Photoshop. 
 
Nissl Stain.  Mouse brains were perfused, prepared and sectioned as described above.  
36μm sections on Fisherbrand Superfrost microscope slides were dried at room 
temperature (RT) overnight.  Samples were placed in 4% PFA for 15 minutes on a rocker 
at RT.  Next, samples were rinsed twice in PBS for 5 minutes each wash at RT.  Samples 
were then soaked in distilled water (DW) for 1 minute.  Samples were then exposed to an 
ethanol gradient for one minute in each: 70, 80, 90, 95, 100, 100%.  Samples placed in 
xylene for 1 minute and then another xylene bath for 30 minutes.  Samples were then 
transferred back to the first xylene bath for one minute and then down the ethanol 
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gradient, in each bath for one minute (100, 100, 95, 90, 80, 75).  Samples were placed in 
DW for one minute.  Next samples were incubated at 42o C for 5 minutes in 0.1% Cresyl 
Violet in DW (previously filtered through 3mm filter paper).  Samples were then washed 
in DW to remove excess stain.  Samples then were exposed to acid ethanol (100% 
ethanol, trace acetic acid) for 5-10 minutes until contrast was appropriate.  Samples were 
transferred to an ethanol gradient for one minute in each concentration (, 80, 90, 95, 100, 
100%).  Samples were then bathed in Histoclear 3 times for 1 minute each.  Slides were 
then coverslipped with Eukitt.  Sections were analyzed using a Zeiss Stemi dissecting 
microscope or a Zeiss AxioImager (Zeiss, Oberkochen, Germany) fitted with an 
AxioCam Mrc5 digital camera. Images were captured using AxioVision AC software 
(Zeiss) and assembled using Adobe Photoshop. 
 
BrdU Assay.  Pregnant mice were subjected to intraperitoneal injections of 5-bromo-2-
deoxyuridine (BrdU) 20μg/g at appropriate embryonic time points measured by date of 
seminal plugging.  For short course experiments, pregnant mice were sacrificed 3 hours 
after injection of BrdU.  Embryos were dissected and fixed in 4% PFA for 2 hours.  Long 
course experiments consisted of post-natal time points (P0 or P2).  At these time points, 
mouse brains were perfused, prepared and sectioned as described above.  Sections were 
mounted on slides and allowed to dry overnight before further processing. All incubation 
and wash steps were performed on a rocker when possible.  The slides were first treated 
with 4% PFA for 15 minutes and wash 3 times for 5 minutes each in DEPC-PBS. For 
mouse stages P0 through P20 the slides were incubated in detergent solution (consisting 
of) for two 15 minute intervals. For older stages, 30 minute incubation periods were used 
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and no detergent treatment was used for embryonic tissue sections. After detergent 
treatment, the slides were washed once in DEPC-PBS and then incubated with proteinase 
K solution (at a concentration of 1.02 μg/ml) for 30 minutes at 37°C.  Slides were fixed 
again in 4% PFA for 15 minutes and then washed three times 5 minutes in DEPC-PBS. 
Then the slides were pre-incubated in in-situ hybridization solution (without riboprobe) at 
70°C overnight.  Slides were washed in Solution X twice for 20 minutes each at 70°C.  
Two TBST washes were performed for 10 minutes each at RT.  Slides were bathed in 2N 
HCL for 30 minutes at RT.  Four washes in 100mM Tris-HCl (pH 8.5) for 5 minutes each 
were performed.  Samples were then washed in TBST, three times, for 5 minutes each.  
Next slides were blocked in 10% lamb serum in TBST for 60 minutes at 4°C.  Anti-BrdU 
antibodies were added to slides and placed at 4oC overnight.  Three washes in TBST for 
15 minutes were done before incubating with anti-fluorophore antibody in 1% lamb 
serum overnight at 4oC.  Slides were washed three times in TBST then developed with 5-
Bromo-4-Chloro-3'-Indolyphosphate p-Toluidine Salt (BCIP) and Nitro-Blue 
Tetrazolium Chloride (NBT).  Afterwards the slides were dehydrated in a series of 
ethanol steps, cleared with Histoclear (a xylene substitute) and cover-slipped. Sections 
were analyzed using a Zeiss Stemi dissecting microscope or a Zeiss AxioImager (Zeiss, 
Oberkochen, Germany) fitted with an AxioCam Mrc5 digital camera. Images were 
captured using AxioVision AC software (Zeiss) and cells counted using ImageJ v1.38 
software (NIH).  Statistical analysis was not performed on these pilot experiments, but 
will be performed in the future. 
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Astrocyte Cultures. Primary astrocytes for FACS analysis were isolated and cultured 
from early post-natal mice (P0-P2) by Leiling Chen MD using an established protocol 
[46]. For the apoptosis experiments, astrocytes were exposed to media containing 20 
mg/ml cycloheximide.  Cells were harvested after 3 hours for FACS analysis. 
 
HUVEC Cultures.  Human umbilical vein endothelial cells (HUVECs) were obtained 
from the Vascular Biology and Transplantation Program at Yale University School of 
Medicine (New Haven, CT).  HUVECs were grown on 0.1% gelatin coated 6-well plates 
using 20% fetal bovine serum (FBS), 1% endothelial cell growth supplement (ECGS) in 
M199.  Media was changed every third day.  Cells were used in experiments between 
passages 3-6.  For experimental conditions, HUVECs were grown to confluence (~2 days 
in culture).  Next, fresh media was supplemented with antibody to β1-integrin (P4C10 or 
TS2/16) or mouse IgG.  Cells were harvested for western blotting after 72 hours of 
incubation. 
 
Western Protocol.  Cells were harvested and total protein from the cells was extracted in 
a lysis buffer (150mM NaCl, 1%Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS, 
50mM Tris-HCl pH 8.0 and protease inhibitors, 1mM Na3V04, 10mg/ml leupeptin, 
10mg/ml aprotinin and 4mM PMSF). Cell lysate was centrifuged, supernatant collected 
and stored at -80oC.  Equal amounts of protein (approximately 50 µg/lane) were loaded 
into a 4-15% gradient polyacrylamide gel, separated by electrophoresis (Bio-Rad 
Laboratories, CA) and transferred onto a PVDF membrane (Bio-Rad Laboratories, CA). 
The membranes were incubated with primary antibody (caspase 3 antibody or anti-β-
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actin [Santa Cruz, CA]) overnight at 4oC.  HRP conjugated secondary antibodies were 
used for visualization. 
 
Annexin/PI Fluorescence Activated Cell Sorting.  Primary astrocyte cultures (GFAP-
Cre;CCM3lox/lox and GFAP-Cre;CCM3lox/+) were trypsinized and washed with PBS.  Cells 
were resuspended in 100μl of Annexin V Incubation Reagent (R and D Systems, 
Minneapolis, MN) per 106 cells for 15 minutes in the dark.  Cells were acquired using a 
FACSCalibur flow cytometer (BD Biosciences).  Analysis was performed using WinMDI 
v2.9.  The astrocyte population was identified by forward and side-scatter properties.  A 
threshold for annexin staining was set using the FITC channel by observing unstained 
(control) populations.  Likewise, propidium iodide fluorescence was measured by using 
the PE channel in unstained (control) populations.  From this data, quadrants were set and 
data acquired.  Statistical analysis was not performed on these pilot experiments, but will 





Cre recombinase mediated recombination of CCM3 loxP sites, under the control 
of the endothelial cell specific promoter Tie2 failed to produce viable offspring which 
were homozygous for the CCM3 lox allele (Tie2-Cre;CCM3lox/lox).  Heterozygous pups, 
Tie2-Cre;CCM3lox/+, were found in an expected Mendalian manner.  Gestational 
sacrifices revealed viable Tie2-Cre;CCM3lox/lox embryos at e9.5.  Analysis of intact yolk 
sacs revealed a difference in vascular development between mutants and controls (Figure 
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21 A and B).  This phenotype was also present at e10.5 (Figure 21 E and F).  At e9.5 and 
e10.5, mutants were readily distinguishable from control littermates, being smaller in size 
and also containing a dilated cardiac region (Figure 21 C, D, G and H).  A beating heart 
was present at e9.5, but was not observed at e10.5.  No change in phenotype or 
developmental stage was apparent between e9.5 and e10.5 mutants. 
Whole mount anti-PECAM staining revealed abnormal formation of the lower 
branchial arches (data not shown).  India ink injected into the ventricle of e9.5 mutants 
Figure 21 e9,5 and E10.5 
Tie2-Cre;Ccm3lox/lox exhibit 
yolk sac and pericardial 
developmental 
abnormalities. E9.5 and 
E10.5 control yolk sacs 
display age appropriate 
vascular tree development (a 
and e).  E9.5 and E10.5 Tie2 
KO yolk sacs retain a 
primitive yolk sac consisting 
of islands of blood, lacking a 
vascular tree (b and f).  E9.5 
and E10.5 embryos exhibit a 
dilated pericardial region 
compared to controls (C, D, 
G and H). 
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failed to travel through the distal caudal aorta (Figure 22).  India ink mostly accumulated 
in the pericardial region in Tie2-Cre;CCM3lox/lox embryos.  Some ink traveled into 
branchial arteries 2 and 3, although these arteries appeared constricted compared to 
control embryos.  Dorsal aortae proximal to the heart were not easily identified in 
hematoxilin and eosin stained sections of e9.5 mutant embryos, but were readily 
identified in control embryos (Figure 23 A and C).  Immunoflourescence of PECAM 
revealed the presence of endothelial cells, although the lumen lacked normal patency 
(Figure 23 B and D). 
GFAPcre 
 
Cre mediated recombination of CCM3 lox sites under the control of the GFAP 
promoter produced viable mutant mice at a frequency lower than the expected Mendelian 
ratio.  GFAP-Cre;CCM3lox/lox pups can be phenotypically identified by gait abnormalities, 
small body habitus and a larger, rounder cranium (data not shown).  Repeat polymerase 
chain reaction on phenotypically similar littermates revealed that there are a few GFAP-
Cre;CCM3lox/+ mice heterozygous for the lox allele which display a dysmorphic 
Figure 22 Tie2-Cre;Ccm3lox/lox embryos fail to develop normal vascular connections. Tie2-
Cre;Ccm3lox/lox E9.5 embryos (b) injected with India ink into the primitive ventricle did not diffuse out 
of the heart, through the branchial arteries and down the dorsal aorta as littermate controls (a). 
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appearance, but not as severe as mutants.  These littermates do not seem to have the gait 
abnormalities seen in the mutants. 
Nissl staining of coronal sections revealed generalized disorganization of the 
cortical layers, hippocampus (including a smaller dentate gyrus) and cerebellum (Figure 
24).  In situ hybridization assaying known markers of cortical layering suggest a 
perturbation in neuron migration from the deeper layers to the more superficial layers of 
the cortex (Figure 25). 
Figure 23 Tie2-Cre;Ccm3lox/lox embryos display abnormal dorsal aortae.  H and E 
staining of E9.5 cross sections revealed an apparent lack of doral aortae in the Tie2-
Cre;Ccm3lox/lox embryos (a and c).  Subsequent immunohistochemistry with PECAM 
revealed the presence of endothelium and dorsal aorta with a significantly smaller lumen 
in the Tie2-Cre;Ccm3lox/lox embryos (b and d). NT = Neural Tube, DA = Dorsal Aorta 
  40 
BrdU assays on cortical sections of embryonic day 14.5 embryos performed 3hr 
after injection of BrdU revealed decreased BrdU staining in cortical areas, excluding the 
ventricular layer (Figure 26).  At e16.5, GFAP-Cre;CCM3lox/lox  mice exhibited less BrdU 
uptake in layers of the somatosensory cortex above the ventricular zone and the basal 
ganglia (Figure 27).  This trend was not observed in the visual cortex. 
GFAP-Cre;CCM3lox/lox  Astrocyte Culture 
 
 Astrocyte cultures isolated from postnatal day 1 GFAP-Cre;CCM3lox/lox  mice and 
GFAP-Cre;CCM3lox/+ mice exposed to cycloheximide and assayed by annexin-PI 
fluorescence activated cell sorting revealed a trend towards resistance to apoptosis in the 
mutant cultures (Figure 28). 
Activation of β-1 integrin increase caspase-3 expression 
 
 The ability of antibodies to activate and block beta-1 integrin function was tested 
in our HUVEC culture conditions.  Interestingly, P4C10, an antibody known to block 
Figure 24 Nissl staining reveals abnormal cytoarchitecture. Adult GFAP-Cre;Ccm3lox/lox (b) 
exhibit generalized disorganization of cortical layers compared to control mice (a).  Development 
of the hippocampus is perturbed; GFAP-Cre;Ccm3lox/lox mice displayed abnormal layering and a 
smaller dentate gyrus. 
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beta-1 integrin signaling [47], [37] decreased expression of caspase-3, as compared to 
control cultures.  Conversely, TS2/16, an antibody known to promote beta-1 integrin 
signaling [48], slightly increased expression of caspase-3 (Figure 29). 
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Figure 25 In situ hybridization on GFAP-
Cre;Ccm3lox/lox sections exhibit abnormal 
development of cerebral cortical and cerebellar 
layers.  Tbr1, SCIP, ephrinA5, CoupTF1 anti-sense 
probes were used to observe the development of 
cortical layers.  Ror-α was used to analyze the 
cerebellum. GFAP-Cre;Ccm3lox/lox (right column) do 
not develop normal cortical layers as seen in control 
mice (left column). 
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Figure 26 Three hour BrdU incorporation differs between GFAP-
Cre;Ccm3lox/lox and GFAP-Cre;Ccm3lox/lox mice. GFAP-Cre;Ccm3lox/lox 
cortical sections (-/-, C and D) exhibit less BrdU incorporation compared to 
GFAP-Cre;Ccm3lox/l+ cortical sections (+/-, A and B).  Quantification was 
achieved with Image J software (E). 
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Figure 27 GFAP-Cre;Ccm3lox/lox and GFAP-Cre;Ccm3lox/+ 
mice differ in the number of dividing cells present in the 
somatosensory cortex and basal ganglia.  BrdU injections were 
performed at E16.5.  Mice were sacrificed and assayed for BrdU 
incorporation at P2. GFAP-Cre;Ccm3lox/lox brains displayed less 
BrdU incorporation in the somatosensory cortex than GFAP-
Cre;Ccm3lox/+ brains (A and B).  This finding was not obvious in 
the visual cortex (C and D). GFAP-Cre;Ccm3lox/lox also exhibited 
less BrdU incorporation in the basal ganglia (E and F).  BrdU 
positive cells were quantified using Image J software (G).  GFAP 
Het = GFAP-Cre;Ccm3lox/+ , GFAP KO = GFAP-Cre;Ccm3lox/lox , 
Ssc = somatosensory cortex, Vc = visual cortex, BG = basal 
ganglia, +/- = GFAP-Cre;Ccm3lox/+ , -/- = GFAP-Cre;Ccm3lox/lox  
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Discussion 
Mice deficient in endothelial cell 
CCM3 are similar to CCM1 
knockouts 
 
 Endothelial cell specific 
knockouts of CCM3 
developmentally arrested around 
e9.5, one day after activation of the 
Tie2 promoter.  Phenotypically, 
these mice resembled CCM1 
homozygous knockout mice.  
Specifically, both CCM1 
homozygous knock-outs and 
endothelial cell specific CCM3 
knock-outs possess yolk sacs which 
lack a normal vascular tree, exhibit 
developmental arrest at e9.5, develop an 
enlarged pericardial region with 
hemorrhage, abnormal branchial arch 
development and lack normal dorsal aorta 
patency proximal to the heart [49].  In 
addition to the above findings, the CCM1 
knock-out mice possessed dilated atria, 
Figure 28 Primary astrocyte culture of 
GFAP-Cre;Ccm3lox/lox brains were resistant 
to cycloheximide induced apoptosis.  Primary 
astrocyte cultures were exposed to 
cycloheximide (20μg/ml) for 3 hrs.  Cells were 
analysed for apoptosis by staining for Annexin 
V.  Flow cytometric analysis revealed fewer 
GFAP-Cre;Ccm3lox/lox astrocytes (C and D) 
entering apoptosis after 3 hrs exposure to 
cycoheximide compared to GFAP-
Cre;Ccm3lox/+ astrocytes (A and B).  
Quantification of 13 primary astrocyte cultures 
(6 GFAP-Cre;Ccm3lox/lox and 7 GFAP-
Cre;Ccm3lox/+) lacked significance, but a trend 
was present between GFAP-Cre;Ccm3lox/lox and 
GFAP-Cre;Ccm3lox/+ cultures which underwent 
treatment with cycloheximide (E). CCM3 +/- = 
GFAP-Cre;Ccm3lox/+ , CCM3 -/- = GFAP-
Cre;Ccm3lox/lox, +/- = GFAP-Cre;Ccm3lox/+ , -/- 
= GFAP-Cre;Ccm3lox/lox, untreated = no 
cycloheximide added to media, treated = media 
with cycloheximide 
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cranial vessels and caudal dorsal aorta.  
Quantification of mitotic endothelial cells in 
dilated vessels revealed increased endothelial cell 
proliferation in dilated vasculature.  CCM1 
knock-out embryos lacked normal expression of 
alpha-smooth muscle actin, an arterial marker.  
Furthermore, immunohistochemical analysis of 
CCM1 knock-out mice revealed decreased 
vascular expression of NOTCH4, which 
corresponds to human CCM [49].  This data 
further supports the hypothesis that CCM1 and 
CCM3 share a common molecular pathway as 
suggested by the similar phenotype in human 
CCM.  Unfortunately, the phenotype alone does not prove CCM3 involvement in the 
CCM1 pathway.  Knock-out mice of other genes important in vasculogenesis develop 
similar phenotypes.  Loss of function mutations in activin receptor-like kinase-1 
(ACVRL1) are known to cause hereditary hemorrhagic telangectasia.  Murine knock-outs 
of ACVRL1 arrest at e9.5, lack an appropriate yolk sac vascular tree, display a dilated 
cardiac region, possess dilated cardinal veins and are deficient of the arterial-specific 
marker Efnb2 [50].  A mouse knock-out of vascular endothelial cell protein tyrosine 
phosphatase, a modulator of Tie2, display arrested development at e9.5, exhibit primitive 
yolk sac development (lacking a vascular tree), are significantly smaller than control 
embryos, develop pericardial edema, and exhibit collapsed dorsal aorta [51].  This data 
Figure 29 A blocker of β1-integrin 
signaling cascade attenuated 
expression of Caspase-3.  HUVECs 
were cultured and allowed to grow to 
confluence.  Western blot analysis was 
performed on cultures after a 3 day 
exposure to a β1-integrin activating 
antibody (TS2/16), a β1-integrin 
blocking antibody (P4C10) and a Mouse 
IgG control.  The β1-integrin blocking 
antibody (middle lane) significantly 
reduced the expression of Caspase-3. 
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raises the question of whether the phenotype our group has found is a common phenotype 
when vasculogenesis is disrupted, or do the CCM’s play a role in Tie2 mediated 
regulation of vascular modeling?  The latter is supported by recent zebrafish experiments.  
Zebrafish harboring mutations in the gene santa (san, homolog of krit1) resulted in 
increased Tie2 expression, suggesting san/krit1 is a negative regulator of endothelial cell 
gene expression. Zebrafish with the san mutation exhibit dilated vessels and an increase 
in endothelial cells similar to that observed in CCM1 knock-out embryos.  Additionally, 
mutations of valentine (vtn, homolog of malcavernin) exhibit cardinal veins with 
decreased luminal diameter [52]. Further studies on the endothelial cell specific CCM3 
knockout mouse are necessary to conclude the extent of phenocopy to CCM1 knockouts. 
CCM3 in Glial affects cortical layering 
 
 In our mouse model, mice deficient of CCM3 in GFAP expressing cell lines 
exhibited severe difficulties with gait.  Our nissl staining, in situ hybridization and 
immunohistochemistry revealed a lack of normal cortical and cerebellar layering.  
Although the cerebellar defects could account for the ataxia, this phenotype cannot be 
conclusively traced to the cerebellum given the extent of abnormal development 
throughout other brain regions, including the basal ganglia and somatosensory cortex.  
The question arises as to what is the cause of the observed dysmorphism?  We have 
observed in previous experiments increased presence of GFAP signal in GFAP-
Cre;CCM3lox/lox cortical sections.  Does this represent an increased number of GFAP 
positive cells?  Our BrdU experiments suggest the contrary.  Fewer dividing cells were 
identified in the GFAP-Cre;CCM3lox/lox  cortex.  The observation of fewer dividing cells 
may be explained by the decrease in neuronal migration as revealed by in situ 
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hybridization.  The cells which normally would be dividing in the cortex may never make 
it out of the ventricular zone.  Or could the increase in GFAP signal represent increased 
astrocytic processes, since GFAP is an intermediate filament?  It is possible that CCM3 
modulates the extent and direction of glia process growth.  A perturbation in this growth 
may lead to aberrant glial processes.  If this is correct, and what we have observed are 
aberrant processes, this is suggestive of a problem in the normal communication glia 
usually undergo with the surrounding environment of extracellular matrix, neurons and 
endothelia.  Moving forward, we will use TUNEL assays on cortical sections to observe 
changes in apoptosis. 
 GFAP-Cre;CCM3lox/+ mice were the only available control mice for the BrdU 
experiments.  In future experiments, comparisons made between WT and GFAP-
Cre;CCM3lox/lox mice  may reveal a greater difference in BrdU labeling in somatosensory 
cortex and possibly the visual cortex. 
GFAP-Cre;CCM3lox/lox  astrocyte cultures are resistant to apoptosis 
 
We utilized flow activated cell sorting to observe apoptosis.  This was the first 
time our group has attempted this technique.   This method has significant advantages to 
other methods of observing apoptosis.  With FACS we are able to observe the whole 
culture.  This decreases the incidence of a sampling error, which may occur when 
choosing fields of a slide on which to perform counts.  In the future, the use of FACS will 
allow us to sort cells based on expression of cell markers.  After sorting, these cells will 
be used for RT-PCR and Western blotting to assess changes in expression of CCM 
pathway modulators. 
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In agreement with our previous PDCD10 siRNA experiments in HUVECs and 
TUNEL assays performed on primary GFAP-Cre;CCM3lox/lox  astrocytes exposed to 
cycloheximide, GFAP-Cre;CCM3lox/lox  astrocytes exhibit less expression of intracellular 
phospholipids on their outer surface than control astrocytes three hours after exposure to 
cycloheximide.  We measured this expression of normally intracellular phospholipids by 
annexin V staining, a known marker of early apoptosis.  Although our data reveals a 
trend towards resistance to apoptosis in the GFAP-Cre;CCM3lox/lox astrocytes, 
significance was not achieved.  This experiment was complicated by a number of factors. 
Analysis of the FACS dot plots reveals that the vast majority of culture, control 
and experimental, did not enter apoptosis after exposure to cycloheximide.  There are at 
least two explanations for this observation.  We introduced cycloheximide to cultures 
after the cultures had reached confluence.  In other experiments using HUVECS, I have 
noticed a decrease in how responsive cultures are to an intervention (antibody or 
chemical) once allowed to grow to confluence.  Cultures have been more responsive to 
intervention when the intervention is performed on cultures around 70-80% confluence.  
Future cycloheximide experiments should be performed before cultures reach confluence.  
Another explanation is that too little cycloheximide was used to induce apoptosis.  We 
used 20 μg/ml of cycloheximide in culture to induce apoptosis.  This concentration has 
been shown to induce apoptosis in approximately 50% of wild-type primary rat astrocyte 
cultures [53].  This is not terribly different from our ability to induce apoptosis in 
approximately 38% of GFAP-Cre;CCM3lox/+ cultures.  Increasing the concentration of 
cycloheximide used under our conditions may induce apoptosis in a higher percentage of 
the culture population.  Unfortunately, heterozygous, GFAP-Cre;CCM3lox/+ , cultures 
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were the only available controls for this set of experiments.  It would be interesting to 
investigate the difference between GFAP-Cre;CCM3lox/lox and WT cultures in response to 
apoptotic stimuli. 
Another complicating factor in our experiments was the lack of purity in our 
astrocyte cultures.  In many of our astrocyte cultures, immunohistochemistry for GFAP 
and staining of DAPI revealed a significant population of cells which were not GFAP 
positive.  Our cultures were often contaminated with another cell type.  The most 
common contaminant in primary astrocyte cultures are fibroblasts.  In our system, 
fibroblasts from GFAP-Cre;CCM3lox/lox brains would normally express CCM3.  These 
cells may not be resistant to apoptosis, as CCM3 deficient cells seem to be.  The 
contamination of our cultures with fibroblast may have been responsible for the lack of 
consistent results as evident by the error bars in figure 8. 
β-1 integrin modulation changed expression of a modulator of caspase-3 
 
 The literature has implicated CCM1 in β-1 integrin signaling through interactions 
with ICAP.  Mounting evidence from our group and others suggest the CCM’s act by 
modulating a common pathway and possibly as a complex.  This present study further 
supports this hypothesis based on the similarities of phenotype between CCM1 mutant 
and our Tie2-CCM3 knock-outs.  Additionally, our GFAP-Cre;CCM3lox/lox mice have 
demonstrated cortical layering perturbations similar to that seen in β1-integrin mutants 
[30]. 
 To further pinpoint CCM3’s role in β1-integrin signaling it will be necessary to 
be able to change β1-integrin signaling.  This could be attempted by changing the 
substrate on which astrocyte cultures will be grown or changing β1-integrin expression.  
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The method we have chosen uses antibodies in cell culture to modify signaling of 
endogenously expressed β1-integrin.  The ability to use P4C10, a known blocker of β1-
integrin signaling, to attenuate caspase-3; coupled with the ability to utilize TS2/16, a 
known potentiator of β1-integrin signaling, to increase caspase-3 expression will allow us 
to further elucidate CCM3’s role in β1-integrin mediated apoptosis, cell migration, 
adhesion and proliferation. 
 
Conclusion 
 The above experiments further support the hypothesis that CCM3 is involved in a 
signaling pathway common to CCM1 and CCM2.  Our Cre;lox mouse model has 
replicated human disease, producing CCM in the GFAP-Cre;CCM3lox/lox mouse, along 
with the dilated vessels often accompanying human CCM.  The findings in the GFAP-
Cre;CCM3lox/lox mouse suggest that CCM3 is important in glia for the prevention of 
CCM, as well as normal cortical development.  Our mouse model differs from human 
CCM in the fact that all GFAP positive cells present in the mouse CNS are deficient in 
CCM3.  In a two-hit hypothesis of familial human CCM, these cells would be 
haploinsufficient.  The acquisition of an additional, random mutation of the functional 
allele could cause the development of CCM without gross abnormalities in cortical 
development. 
 Future experiments could utilize  a Cre-recombinase expressing adenovirus.  This 
virus injected into the CNS of Cre;CCM3lox/lox mice would afford us greater temporal and 
spatial control of CCM3 attenuation.  It would be interesting to see if this method would 
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lead to CCM formation.  It would also be interesting to know if loosing CCM3 function 
and subsequent CCM formation is dependent on the stage of development. 
 Our mouse model, combined with primary cell cultures obtained from our mice, 
has been useful in elucidating CCM3 function.  With the discovery of a CCM in one of 
the mutant mice, this system may be a useful model of human disease.  Our methods will 
continue to be useful in further clarifying the pathogenesis of cerebral cavernous 
malformations. 
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